TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle

Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.

Zacks Investment Research • May 8, 2026

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

YUPELRI ® Collaboration Revenue increased 15% year-over-year 1 , from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage All Hatch-Waxman litigation relating to YUPELRI ® has been resolved following settlement with Mankind Pharma in March Organizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items) Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment 2 Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder value Quarter-end cash balance of $395 million and no debt DUBLIN, May 7, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2026. "We delivered strong financial performance in the first quarter, reinforcing the quality of our commercial asset, our robust balance sheet and the important actions underway to reshape our cost structure, following the outcome of the CYPRESS study," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma.

PRNewsWire • May 7, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • May 7, 2026

Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • May 7, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

GlobeNewsWire • Apr 21, 2026

Theravance Stock Declines Around 17% in Three Months: Here's Why

TBPH shares sink in three months after its lead drug fails a late-stage study, forcing a pipeline overhaul and raising uncertainty over its future direction.

Zacks Investment Research • Apr 16, 2026

TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates

Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment NEW YORK, April 15, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders who lost money are encouraged to submit their information now.

PRNewsWire • Apr 15, 2026

TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $TBPH--TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm.

Business Wire • Apr 3, 2026

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.

Zacks Investment Research • Apr 2, 2026

TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP

Theravance Biopharma Reaffirmed Financial Guidance Repeatedly Without Disclosing the Material Risk That Its Pivotal Trial Could Fail Theravance Biopharma Reaffirmed Financial Guidance Repeatedly Without Disclosing the Material Risk That Its Pivotal Trial Could Fail

GlobeNewsWire • Mar 26, 2026